Impact of Androgen Suppression Therapy on the Risk and Prognosis of Bladder Cancer: A Systematic Review and Meta-Analysis.
Impact of Androgen Suppression Therapy on the Risk and Prognosis of Bladder Cancer: A Systematic Review and Meta-Analysis.
复制标题
雄激素抑制治疗对膀胱癌风险和预后的影响：系统评价和荟萃分析
DOI：
10.3389/fonc.2021.784627
复制
发表时间：
2021
影响因子：
4.7
通讯作者：
Ping H
中科院分区：
文献类型：
--
作者：
Xiang P;Du Z;Hao Y;Guan D;Liu D;Yan W;Wang M;Liu Y;Ping H
目的本研究的目的是总结现有证据，并对雄激素抑制治疗（AST）对膀胱癌发病率或临床结局的影响进行全面的系统评价。方法我们系统性地检索了PubMed和Embase数据库，从开始到2021年6月20日，以确定所有观察性研究，这些研究检查了接受AST治疗的患者中膀胱癌的发病率或临床结局。AST定义为使用5-α还原酶抑制剂（5-阿里斯）或雄激素剥夺治疗（ADT）。结果共纳入18个观察性研究。我们的研究结果表明，与缺乏AST相比，AST与BCa发病率风险降低无显著相关性（OR：0.92，95%CI：0.68-1.24）。亚组分析显示，使用非那肽与BCa发生率风险降低显著相关（OR：0.75，95% CI：0.64-0.88）。与非使用者相比，AST使用者的无复发生存期（RFS）有所改善（HR：0.68，95% CI：0.48-0.95），而AST使用者与非使用者之间的癌症特异性生存期（CSS）、总生存期（OS）或无进展生存期（PFS）无显著差异。结论目前的证据表明，非那肽治疗可能是一种潜在的策略，旨在降低BCa的发病率。此外，AST对膀胱癌的复发具有有益作用。需要进一步设计良好的随机试验或具有更好特征的研究人群的队列研究来验证我们的初步研究结果。系统性评价注册国际前瞻性系统性评价注册数据库[https：//www.crd.york.ac.uk/PROSPERO/]，标识符CRD 42021261685。
Purpose The purpose of this study was to summarize the existing evidence and develop a comprehensive systematic review of the impact of androgen suppression therapy (AST) on the incidence or clinical outcomes of bladder cancer. Methods We systematically searched the PubMed and Embase databases from inception to June 20, 2021 to identify all observational studies examining the incidence or clinical outcomes of bladder cancer in patients who received AST. AST is defined as the use of 5-alpha reductase inhibitors (5-ARIs) or androgen deprivation therapy (ADT). Results A total of 18 observational studies were included. Our results showed that AST was not significantly associated with a reduced risk of BCa incidence (OR: 0.92, 95% CI: 0.68–1.24) compared with the lack of AST. The subgroup analysis revealed that finasteride use was significantly associated with a reduction in the risk of BCa incidence (OR: 0.75, 95% CI: 0.64–0.88). Recurrence-free survival (RFS) was improved among AST users compared with nonusers (HR: 0.68, 95% CI: 0.48–0.95), while no significant difference between AST users versus nonusers was identified for cancer-specific survival (CSS), overall survival (OS) or progression-free survival (PFS). Conclusion Current evidence indicates that therapy with finasteride may represent a potential strategy aimed at reducing BCa incidence. Moreover, AST has a beneficial effect on the recurrence of bladder cancer. Further well-designed randomized trials or cohort studies with better characterized study populations are needed to validate our preliminary findings. Systematic Review Registration International Prospective Register of Systematic Reviews database [https://www.crd.york.ac.uk/PROSPERO/], identifier CRD42021261685.
登录
查看更多内容
DOI：
10.4103/iju.iju_320_19
发表时间：
2020-07
期刊：
Indian journal of urology : IJU : journal of the Urological Society of India
影响因子：
--
作者：
Moorthy HK;Prabhu GGL;Venugopal P
通讯作者：
Venugopal P
DOI：
10.3390/diagnostics11020351
发表时间：
2021-02-20
期刊：
Diagnostics (Basel, Switzerland)
影响因子：
--
作者：
Creta M;Celentano G;Napolitano L;La Rocca R;Capece M;Califano G;Collà Ruvolo C;Mangiapia F;Morra S;Turco C;Spirito L;Fusco F;Imbimbo C;Mirone V;Longo N
通讯作者：
Longo N
影响因子：
5.5
作者：
Martínez-Rojo E;Berumen LC;García-Alcocer G;Escobar-Cabrera J
通讯作者：
Escobar-Cabrera J
影响因子：
6.6
作者：
Luna-Velez MV;Dijkstra JJ;Heuschkel MA;Smit FP;van de Zande G;Smeets D;Sedelaar JPM;Vermeulen M;Verhaegh GW;Schalken JA
通讯作者：
Schalken JA
使用抗雄激素 Enzalutamide 靶向雄激素受体 (AR)，通过差异改变 AR/circRNA-ARC1/miR-125b-2-3p 或 miR-4736/PPAR·§/MMP-9 信号，增加前列腺癌细胞侵袭，同时减少膀胱癌细胞侵袭
影响因子：
12.4
作者：
Deng G;Wang R;Sun Y;Huang CP;Yeh S;You B;Feng C;Li G;Ma S;Chang C
通讯作者：
Chang C